36 Les biomarqueurs moléculaires en oncologie
Conclusion
À l’ère de la médecine personnalisée, la conception d’un nouvel agent
non cytotoxique ne peut donc être similaire à celle d’un agent cytotoxique.
,OOHVWWQpFHVVDLUHHG¶LGHQWL¿HUUODDFLEOHHHWWVDDSHUWLQHQFHHWWGHHSRVVpGHUUXQQWHVWW
qui permettrait de prédire la réponse tumorale à cet agent.
Références
1. Pharmaceutical Research and Manufacturers of America (phRMA). Medecines in
developpement for cancer. http://www.phrma.org
2. US Departement of Health and Human Services Food and Drug Administration.
Innovation or stagnation: challenges and opportunity on the critical path to new medical
products. US Department of Health and Human Services; 20047; http://www.fda.gov/oc/
initiatives/criticalpath/withepaper.html
3. Andre F, Job B, Dessen P, et al. (2009) Molecular characterization of breast cancer with
l l
high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res
15: 441-51
4. Korn EL (2004) Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic
agents. J Natl Cancer Inst 96, 977-78
5. Von Hoff DD, LoRusso PM, Rudin CM, et al. (2009) Inhibition of the hedgehog pathway
l l
in advanced basal-cell carcinoma. New Engl J Med 361: 1164-72
6. Kwak E, Cadmige D, Clark J. Clinical activity observed in a phase I dose escalation trial
of an oral c-met and ALK inhibitor, PF-02341066 -- Kwak et al. 27(15): 3509 -- ASCO
Meeting Abstracts, http://meeting.ascopubs.org/cgi/content/abstract/27/15S/3509
7. Kinders R, Parchment RE, Ji J, et al. (2007) Phase 0 clinical trials in cancer drug
development: from FDA guidance to clinical practice. Mol Interv 7(6): 325-34
8. Kummar S, Kinders R, Gutierrez ME, et al. (2009) Phase 0 clinical trial of the poly
(ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies, J
Clin Oncol 27: 2705-11
9. Wistuba II, Gelovani JG, Jacoby JJ, et al. (2011) Methodological and practical challenges
for personalized cancer therapies. Nat Rev Clin Oncol 8(3): 135-41
10. Jayson GC, Zweit J, Jackson A, et al. (2002) Molecular imaging and biological evaluation of
HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.
J Natl Cancer Inst 94(19): 1484-93
Conclusion
À l’ère de la médecine personnalisée, la conception d’un nouvel agent
non cytotoxique ne peut donc être similaire à celle d’un agent cytotoxique.
,OOHVWWQpFHVVDLUHHG¶LGHQWL¿HUUODDFLEOHHHWWVDDSHUWLQHQFHHWWGHHSRVVpGHUUXQQWHVWW
qui permettrait de prédire la réponse tumorale à cet agent.
Références
1. Pharmaceutical Research and Manufacturers of America (phRMA). Medecines in
developpement for cancer. http://www.phrma.org
2. US Departement of Health and Human Services Food and Drug Administration.
Innovation or stagnation: challenges and opportunity on the critical path to new medical
products. US Department of Health and Human Services; 20047; http://www.fda.gov/oc/
initiatives/criticalpath/withepaper.html
3. Andre F, Job B, Dessen P, et al. (2009) Molecular characterization of breast cancer with
l l
high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res
15: 441-51
4. Korn EL (2004) Nontoxicity endpoints in phase I trial designs for targeted, non-cytotoxic
agents. J Natl Cancer Inst 96, 977-78
5. Von Hoff DD, LoRusso PM, Rudin CM, et al. (2009) Inhibition of the hedgehog pathway
l l
in advanced basal-cell carcinoma. New Engl J Med 361: 1164-72
6. Kwak E, Cadmige D, Clark J. Clinical activity observed in a phase I dose escalation trial
of an oral c-met and ALK inhibitor, PF-02341066 -- Kwak et al. 27(15): 3509 -- ASCO
Meeting Abstracts, http://meeting.ascopubs.org/cgi/content/abstract/27/15S/3509
7. Kinders R, Parchment RE, Ji J, et al. (2007) Phase 0 clinical trials in cancer drug
development: from FDA guidance to clinical practice. Mol Interv 7(6): 325-34
8. Kummar S, Kinders R, Gutierrez ME, et al. (2009) Phase 0 clinical trial of the poly
(ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies, J
Clin Oncol 27: 2705-11
9. Wistuba II, Gelovani JG, Jacoby JJ, et al. (2011) Methodological and practical challenges
for personalized cancer therapies. Nat Rev Clin Oncol 8(3): 135-41
10. Jayson GC, Zweit J, Jackson A, et al. (2002) Molecular imaging and biological evaluation of
HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies.
J Natl Cancer Inst 94(19): 1484-93